Use of selexipag in a teenage patient with pulmonary arterial hypertension
We report the case of a teenage patient with idiopathic PAH who presented in World Health Organization functional Class IV and showed no clinical improvement with dual therapy. We added oral selexipag to the treatment regimen and observed substantial improvement in her quality of life at the short-time follow-up. Despite the lack of childhood data regarding the use of selexipag in pediatric patients with PAH, the use of this drug in the current teenage patient improved her quality of life and exercise capacity.
Source: Annals of Pediatric Cardiology - Category: Cardiology Authors: Nathalie Jeanne Magioli Bravo-Valenzuela Flavia Navarro Socrates Pereira Silva Source Type: research
More News: Cardiology | Heart | Hypertension | International Medicine & Public Health | Pediatrics | Sports Medicine | WHO